Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19.
Arch Microbiol
; 206(2): 69, 2024 Jan 19.
Article
en En
| MEDLINE
| ID: mdl-38240823
ABSTRACT
The nuclear export protein 1 (XPO1) mediates the nucleocytoplasmic transport of proteins and ribonucleic acids (RNAs) and plays a prominent role in maintaining cellular homeostasis. XPO1 has emerged as a promising therapeutic approach to interfere with the lifecycle of many viruses. In our earlier study, we proved the inhibition of XPO1 as a therapeutic strategy for managing SARS-COV-2 and its variants. In this study, we have utilized pharmacophore-assisted computational methods to identify prominent XPO1 inhibitors. After several layers of screening, a few molecules were shortlisted for further experimental validation on the in vitro SARS-CoV-2 cell infection model. It was observed that these compounds reduced spike positivity, suggesting inhibition of SARS-COV-2 infection. The outcome of this study could be considered further for developing novel antiviral therapeutic strategies against SARS-CoV-2.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
COVID-19
/
Proteína Exportina 1
Límite:
Humans
Idioma:
En
Revista:
Arch Microbiol
Año:
2024
Tipo del documento:
Article